Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells

被引:84
作者
Li, SY [1 ]
Tokuyama, T [1 ]
Yamamoto, J [1 ]
Koide, M [1 ]
Yokota, N [1 ]
Namba, H [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 4313192, Japan
关键词
herpes simplex virus thymidine kinase; ganciclovir; bystander effect; neural stem cell; glioma;
D O I
10.1038/sj.cgt.7700826
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Since neural stem cells (NSCs) have the ability to migrate toward a tumor mass, genetically engineered NSCs were used for the treatment of gliomas. We first evaluated the "bystander effect'' between NSCs transduced with the herpes simplex virus-thymidine kinase (HSVtk) gene (NSCtk) and C6 rat glioma cells under both in vitro and in vivo conditions. A potent bystander effect was observed in co-culture experiments of NSCtk and C6 cells. In the intracranial co-implantation experiments in athymic nude mice and Sprague - Dawley rats, the animals co-implanted with NSCtk and C6 cells and treated with ganciclovir (GCV) showed no intracranial tumors and survived more than 100 days, while those treated with physiological saline ( PS) died of tumor progression. We next injected NSCtk cells into the pre-existing C6 tumor in rats and treated them with GCV or PS. The tumor volume was serially measured by magnetic resonance imaging. The tumor disappeared in six out of nine rats in the NSCtk/GCV group, while all the rats treated with PS died of tumor progression by day 21. The results indicate the feasibility of a novel gene therapy strategy for gliomas through a bystander effect generated by intratumoral injection of NSCtk cells and systemic GCV administration.
引用
收藏
页码:600 / 607
页数:8
相关论文
共 23 条
[1]   Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas [J].
Aboody, KS ;
Brown, A ;
Rainov, NG ;
Bower, KA ;
Liu, SX ;
Yang, W ;
Small, JE ;
Herrlinger, U ;
Ourednik, V ;
Black, PM ;
Breakefield, XO ;
Snyder, EY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (23) :12846-12851
[2]   Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy [J].
Barresi, V ;
Belluardo, N ;
Sipione, S ;
Mudó, G ;
Cattaneo, E ;
Condorelli, DF .
CANCER GENE THERAPY, 2003, 10 (05) :396-402
[3]   Gene therapy of experimental brain tumors using neural progenitor cells [J].
Benedetti, S ;
Pirola, B ;
Pollo, B ;
Magrassi, L ;
Bruzzone, MG ;
Rigamonti, D ;
Galli, R ;
Selleri, S ;
Di Meco, F ;
De Fraja, C ;
Vescovi, A ;
Cattaneo, E ;
Finocchiaro, G .
NATURE MEDICINE, 2000, 6 (04) :447-450
[4]   INVIVO GENE-TRANSFER WITH RETROVIRAL VECTOR PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN-TUMORS [J].
CULVER, KW ;
RAM, Z ;
WALLBRIDGE, S ;
ISHII, H ;
OLDFIELD, EH ;
BLAESE, RM .
SCIENCE, 1992, 256 (5063) :1550-1552
[5]  
Ehtesham M, 2002, CANCER RES, V62, P7170
[6]  
Ehtesham M, 2002, CANCER RES, V62, P5657
[7]  
Hamel W, 1996, CANCER RES, V56, P2697
[8]  
Lee J, 2003, CANCER RES, V63, P8877
[9]   Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum [J].
Lundberg, C ;
MartinezSerrano, A ;
Cattaneo, E ;
McKay, RDG ;
Bjorklund, A .
EXPERIMENTAL NEUROLOGY, 1997, 145 (02) :342-360
[10]  
MOOLTEN FL, 1986, CANCER RES, V46, P5276